Literature DB >> 8592173

Long-term memory deficits in patients with malignant gliomas.

P Salander1, T Karlsson, T Bergenheim, R Henriksson.   

Abstract

Knowledge about the neuropsychological performance of adult patients with brain tumors, and especially with malignant gliomas, is limited. In this study 30 patients were consecutively included at time of diagnosis. Five months after completion of radiotherapy eleven of the patients showed no signs of focal neurology or tumor recurrence. These eleven patients, and their partners, were interviewed independently. Using each partner as control the patients were assessed neuropsychologically with special emphasis on memory abilities. The selective reminding technique was used with nouns of different visual imagery. A consistent pattern was found: there was no clear impairment in global intellectual abilities, but there was a pronounced deficit in long-term memory. However, the patients had a preserved capacity to use visual imagery to boost performance. It is important that medical staff acknowledge or confirm this problem. The sparing of imaginal coding makes it possible for the staff to assist with advice facilitating memory. Memory is a vital cognitive ability and the selective reminding technique was a sensitive method capable of detecting subtle impairments. The technique is recommended in future examinations of conditions and evaluations of treatments affecting the CNS.

Entities:  

Mesh:

Year:  1995        PMID: 8592173     DOI: 10.1007/bf01053156

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  23 in total

1.  Memory disturbances in third ventricle tumours.

Authors:  M WILLIAMS; J PENNYBACKER
Journal:  J Neurol Neurosurg Psychiatry       Date:  1954-05       Impact factor: 10.154

2.  Should all patients with malignant astrocytoma have postoperative radiotherapy?

Authors:  A Snijders-Keilholz; J H Voormolen; J Hermans; G W Padberg; J Davelaar; J W Leer
Journal:  Acta Neurochir (Wien)       Date:  1991       Impact factor: 2.216

3.  Assessment of quality of life in patients treated for low-grade glioma: a preliminary report.

Authors:  M J Taphoorn; J J Heimans; F J Snoek; J Lindeboom; B Oosterink; J G Wolbers; A B Karim
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-05       Impact factor: 10.154

4.  Reliability of a Standardized Mini-Mental State Examination compared with the traditional Mini-Mental State Examination.

Authors:  D W Molloy; E Alemayehu; R Roberts
Journal:  Am J Psychiatry       Date:  1991-01       Impact factor: 18.112

5.  Cognitive functions and quality of life in patients with low-grade gliomas: the impact of radiotherapy.

Authors:  M J Taphoorn; A K Schiphorst; F J Snoek; J Lindeboom; J G Wolbers; A B Karim; P C Huijgens; J J Heimans
Journal:  Ann Neurol       Date:  1994-07       Impact factor: 10.422

6.  Good performance status of long-term disease-free survivors of intracranial gliomas.

Authors:  L Kleinberg; K Wallner; M G Malkin
Journal:  Int J Radiat Oncol Biol Phys       Date:  1993-04-30       Impact factor: 7.038

7.  Effects of radiation therapy on adult brain behavior: evidence for a rebound phenomenon in a phase 1 trial.

Authors:  C Armstrong; J Mollman; B W Corn; J Alavi; M Grossman
Journal:  Neurology       Date:  1993-10       Impact factor: 9.910

8.  Cognitive functioning in long-term survivors of high-grade glioma.

Authors:  Y M Archibald; D Lunn; L A Ruttan; D R Macdonald; R F Del Maestro; H W Barr; J H Pexman; B J Fisher; L E Gaspar; J G Cairncross
Journal:  J Neurosurg       Date:  1994-02       Impact factor: 5.115

9.  Neuropsychological correlates of rapidly vs. slowly growing intrinsic cerebral neoplasms.

Authors:  J Hom; R M Reitan
Journal:  J Clin Neuropsychol       Date:  1984-08

Review 10.  Hemispheric encoding/retrieval asymmetry in episodic memory: positron emission tomography findings.

Authors:  E Tulving; S Kapur; F I Craik; M Moscovitch; S Houle
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-15       Impact factor: 11.205

View more
  7 in total

1.  A randomized trial of cognitive rehabilitation in cancer survivors.

Authors:  M M Cherrier; K Anderson; D David; C S Higano; H Gray; A Church; S L Willis
Journal:  Life Sci       Date:  2013-09-05       Impact factor: 5.037

2.  The course of neurocognitive functioning in high-grade glioma patients.

Authors:  Ingeborg Bosma; Maaike J Vos; Jan J Heimans; Martin J B Taphoorn; Neil K Aaronson; Tjeerd J Postma; Henk M van der Ploeg; Martin Muller; W Peter Vandertop; Ben J Slotman; Martin Klein
Journal:  Neuro Oncol       Date:  2006-10-03       Impact factor: 12.300

3.  Facets and determinants of quality of life in patients with recurrent high grade glioma.

Authors:  A R Giovagnoli; A Silvani; E Colombo; A Boiardi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-04       Impact factor: 10.154

4.  Allocentric visuospatial processing in patients with cerebral gliomas: a neurocognitive assessment.

Authors:  V Jagaroo; M P Rogers; P M Black
Journal:  J Neurooncol       Date:  2000-09       Impact factor: 4.130

5.  Acute neurocognitive impairment during cranial radiation therapy in patients with intracranial tumors.

Authors:  Grit Welzel; Katharina Fleckenstein; Sabine K Mai; Brigitte Hermann; Uta Kraus-Tiefenbacher; Frederik Wenz
Journal:  Strahlenther Onkol       Date:  2008-12-24       Impact factor: 3.621

6.  Improved hippocampal dose with reduced margin radiotherapy for glioblastoma multiforme.

Authors:  Arif N Ali; Tomi Ogunleye; Claire W Hardy; Hui-Kuo Shu; Walter J Curran; Ian R Crocker
Journal:  Radiat Oncol       Date:  2014-01-10       Impact factor: 3.481

7.  Mass Effect Deformation Heterogeneity (MEDH) on Gadolinium-contrast T1-weighted MRI is associated with decreased survival in patients with right cerebral hemisphere Glioblastoma: A feasibility study.

Authors:  Prateek Prasanna; Jhimli Mitra; Niha Beig; Ameya Nayate; Jay Patel; Soumya Ghose; Rajat Thawani; Sasan Partovi; Anant Madabhushi; Pallavi Tiwari
Journal:  Sci Rep       Date:  2019-02-04       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.